Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tiragolumab + Atezolizumab in ESCC
NCT05743504Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
tiragolumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05743504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743504.